Biotech Acquisition Company
Status: Liquidated
U=S+W/2
W=S@11.5
| IPO Proceeds, $M | $230.00M |
|---|---|
| IPO Date | Jan 26, 2021 |
| CEO | Laxmi Prasad Palaypu |
| Left Lead | Cantor Fitzgerald |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
The healthcare industry, with a particular focus on life sciences/biotechnology, healthcare information technology, medical technology and technology-enabled healthcare services |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | Jan 19, 2023 |
| Closing Date | Feb 3, 2023 |
BIOT
BIOTU
BIOTW
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Biotech Acquisition Company:
- Structure and cap table
- 6 directors & officers
- 33 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Laxmi Prasad Palaypu | 57 | CEO & Director |
| Jon Paul | 69 | CFO |
| Karl Adam Schoene | 61 | Director |
| Mark Zorko | 70 | Director |
| Elizabeth Ann Levy-Navarro | 59 | Director |
| Gerald P. O’Connor | 71 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
| Underwriters | |||
|---|---|---|---|
| Cantor Fitzgerald | BR | 20,000,000 | units |
| 20,000,000 | units | ||
| Up-Front UW fee | 1.74 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.